Displaying 1 - 20 of 5047
Statement of Chairwoman Edith Ramirez and Commissioner Julie Brill Federal Trade Commission - In the Matter of Ferrellgas Partners, L.P., et al.
Federal Trade Commission Act
Clayton Act
FTC and DOJ Issue Fiscal Year 2025 Hart-Scott-Rodino Annual Report
Caremark Rx, Zinc Health Services, et al., In the Matter of (Insulin)
The FTC filed a lawsuit against the three largest prescription drug benefit managers (PBMs)—Caremark Rx, Express Scripts (ESI), and OptumRx—and their affiliated group purchasing organizations (GPOs) for engaging in anticompetitive and unfair rebating practices that have artificially inflated the list price of insulin drugs.
On February 4, 2026, the Federal Trade Commission secured a landmark settlement with Express Scripts, Inc., and its affiliated entities (collectively “ESI”). The settlement requires ESI to adopt fundamental changes to its business practices that increase transparency, are expected to drive down patients’ out-of-pocket costs for drugs like insulin by up to $7 billion over 10 years, bring millions of dollars in new revenue to community pharmacies each year, and advance the Trump Administration’s key healthcare priorities.
FTC Secures Agreement with Havas to Restore Competition in the Digital Advertising Ecosystem
FTC Files Amicus Brief to Protect Consumers from Pharmaceutical Monopolies
CareFirst of Maryland, et al., Plaintiffs-Appellants, v. Johnson & Johnson, et al., Defendants-Appellees.
FTC Approves Final Consent Order in Pest-Control Noncompete Matter
Rollins Inc., In the Matter of
FTC Takes Action to Protect Americans from Higher Drug Costs in Aurobindo, Lannett Deal
Aurobindo-Lannett, In the Matter of
The FTC is requiring Aurobindo Pharma Limited to divest four different generic drug products to complete its $250 million acquisition of Lannett Company Inc.